BNTC Stock Forecast: Benitec Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.93
−2.64% on the day

The median 12-month analyst price target for Benitec Biopharma, Inc. is $24. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$294.0M
Ticker Nerd rank
39/ 100
Median analyst target
$24
Analysts covering
8
Revenue$0.0
Operating income−$13.6M
Net income−$11.9M
Free cash flow−$4.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.3%
1M
−12.3%
YTD
−41.2%
1Y
−39.7%
From 52W high
−43.7%
From 52W low
0.0%
$8
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Benitec Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
75
Quality
71
Volatility
68
Value
53
Revisions
41
Issuance
29
Growth
20
Momentum
19

Accruals (75): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (19): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BNTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BNTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26BNTCHigh $32Median $24Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8
Buy
0
Hold
0
Sell
$17
Low
$24
Median
$32
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026Leerink PartnersMaintainsOutperform$18 → $18
16 Nov 2026WedbushMaintainsOutperform$17 → $20
23 Oct 2026Raymond JamesInitiatesOutperform$14
15 Sept 2026WedbushMaintainsOutperform$16 → $17
28 July 2026WedbushInitiatesOutperform$16
12 May 2026Evercore ISI GroupInitiatesOutperform$25
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
4 Nov 2025CitizensMaintainsMarket Outperform—
4 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Sept 2025JMP SecuritiesReiteratesMarket Outperform—
16 Sept 2025OppenheimerMaintainsOutperform—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
15 May 2025JMP SecuritiesReiteratesMarket Outperform—
10 Apr 2025JMP SecuritiesMaintainsMarket Outperform—
24 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
21 Feb 2025HC Wainwright & Co.ReiteratesBuy—
13 Dec 2024BairdInitiatesOutperform—
3 Dec 2024GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BNTC.

Market Radar

This page is one stock. Monday covers all of them.

BNTC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BNTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Benitec Biopharma, Inc. returned −39.7% against +6.9% for the S&P 500, dividends included.

BNTC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26BNTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BNTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.7×

Cheaper than 50% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−37.6%

Higher than 25% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Benitec Biopharma, Inc. has a market value of $294.0M and an enterprise value of $118.3M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$48.9M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$19.8M.

  • Shares outstanding: 34.4M.

  • Benitec Biopharma, Inc. employs 24 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

BNTC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BNTCBenitec Biopharma, Inc.$294.0M39
GLSIGreenwich LifeSciences, Inc.$282.6M53
FULCFulcrum Therapeutics, Inc.$281.5M35
EVMNEvommune, Inc.$291.1M11
RLMDRelmada Therapeutics, Inc.$274.8M55
XFORX4 Pharmaceuticals, Inc.$297.4M65
SPRYARS Pharmaceuticals, Inc.$297.6M13

Take a look at BNTC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Benitec Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BNTC

What is the BNTC stock price forecast for 2026-2027?

The median 12-month analyst price target for Benitec Biopharma, Inc. is $24, with estimates ranging from $17 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BNTC stock a buy right now?

Of the 8 analysts covering Benitec Biopharma, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Benitec Biopharma, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BNTC?

As at 21 Nov 2026, Benitec Biopharma, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (75 of 100).

Will BNTC stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts is $24, and Ticker Nerd's factor model ranks Benitec Biopharma, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BNTC stock forecast for 2030?

No analyst covering Benitec Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $32 over the next 12 months.

How has BNTC stock performed over the past year?

Benitec Biopharma, Inc. returned -39.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Benitec Biopharma, Inc. do?

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform. The company combines RNA interference with gene therapy to create treatments designed to silence disease-causing genes while also delivering functional gene replacement in a single administration.

Company

About Benitec Biopharma, Inc.

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines using its proprietary Silence and Replace platform. The company combines RNA interference with gene therapy to create treatments designed to silence disease-causing genes while also delivering functional gene replacement in a single administration. Its current work centers on ddRNAi-based therapeutics for chronic and life-threatening conditions, with a particular emphasis on rare genetic disorders such as oculopharyngeal muscular dystrophy. Benitec Biopharma’s pipeline reflects a precision medicine approach aimed at addressing unmet needs in genetic disease through targeted, durable molecular intervention. Headquartered in Hayward, California, Benitec Biopharma Inc. operates in the biotechnology and gene therapy sectors, where it contributes to the development of advanced platform-based therapies for difficult-to-treat human diseases.

CEO Dr. Jerel A. Banks M.D., Ph.D. · 24 employees · United States · https://benitec.com